Next Science (ASX:NXS) share price jumps on record revenue growth

A surge in revenue during the first half of 2021 puts the Next Science share price in the green today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Next Science Ltd (ASX: NXS) share price is charging higher today.

At the time of writing, the medical technology company's shares are up 4.05% to $1.54.

medical doctor performing surgery using surgical instruments

Image source: Getty Images

Why is the Next Science share price rallying today?

Investors are looking at the Next Science share price more optimistically following the release of its second quarter update.

According to the release, the company pulled in US$3.9 million in revenue for the first half. This reflected an increase of 271% on the prior corresponding period.

Pleasingly for shareholders, this was a record rate of growth from Next Science.

Additionally, its XPerience No Rinse Antimicrobial Solution was cleared by the United States Food and Drug Administration.

The solution helps prevent surgical site biofilm based infections.

The approval process for use in US hospitals is now underway.

Furthermore, Next Science's antimicrobial wound gel, BlastX returned to the company and sales commenced.

Next Science regained the global distribution rights to BlastX from 3M (NYSE: MMM) in April 2021.

The patented medical product has also received approval from Australia's Therapeutic Goods Administration (TGA).

After burning through US$1.9 million in cash during the first half, the company maintains US$13.2 million cash on hand.

Managing Director commentary

Managing Director, Judith Mitchell spoke about the record result for the company:

The strategies we are executing to commercialise our proprietary Xbio technology platform are delivering record results. The 271% revenue growth we have reported for 1H was driven by sales from our existing products.

Following the approval of our market leading "no rinse antimicrobial solution", XPerience, by the FDA on 23 April, we are building an excellent platform for future growth. Our focus has been to secure VAC approvals across US hospitals to facilitate commercial sales in the US. As at mid-July, we had made 123 VAC submissions covering 211 hospitals and we had received 20 approvals.

Next Science share price snapshot

Thanks to today's gains, the Next Science share price is 18.46% higher over the past year.

However, investors who bought at the 52-week high of $2.06 in June are still down 25.24%.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Next Science Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Girl with painted hands.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing Tuesday for investors.

Read more »

Two happy and excited friends in euphoria holding a smartphone, after winning in a bet.
Share Gainers

Why Artrya, Cleanaway, DroneShield, and Nuix shares are pushing higher today

These shares are outperforming on Tuesday. But why?

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Share Market News

4 ASX shares tipped to fly 100% to 125% higher

Brokers rate all of these ASX shares a strong buy.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why Navigator Global, St Barbara, Vulcan Energy, and Zip shares are racing higher today

These shares are starting the week in a positive fashion. But why?

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Share Gainers

3 ASX 200 stocks leaping higher in this week's slumping market

Investors sent these three ASX 200 stocks rocketing 24% to 28% in this week’s sliding market. But why?

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Eden Innovation, Elsight, Paladin Energy, and Zip shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

A female superhero dressed in shiny green with a mask leaps in the sky with leg and arm outstretched in a leaping action.
Share Gainers

WiseTech shares rocket 11% higher today: Buy, sell or hold?

It looks like we could see a lot more out of WiseTech shares over the next few months!

Read more »

Ecstatic man giving a fist pump in an office hallway.
Share Gainers

Why AMP, Life360, Netwealth, and Ora Banda shares are racing higher today

These shares are having a strong session. What's going on?

Read more »